$ETII Update on CBD Pet Products and mentioned in NASDAQ Article
The common benefits of CBD in dogs
Current research shows that there are several common CBD benefits for dogs, which are, 1) powerful painkiller (the ECS is involved in managing pain and CBD's pain killing properties are well documented}; 2) effective anticonvulsant (CBD helps control seizures, tremors, tics and spasms); 3) natural anti-inflammatory; 4) anxiety and stress reducer (anxiety in dogs often results in in barking, urination and defecation, chewing and aggression); 5) active antiemetic (reduces nausea and vomiting); and homeostasis promoter (proper functioning of the body).
"Pet owners are committed to their pet's health well-being and are willing to spend money on pet health products, which make this a multi-billion dollar market, worldwide," said Karren. "We hope to introduce our CBD pet products in 2019 as we believe that our CBD pet products will be superior to those currently offered in this huge industry and will create another profitable channel for our CBD products."
ETII was also mentioned in a NASDAQ article released today with a few other top name CBD brands:
nasdaq.com/press-release/envirotechnologies-internationals-subsidiary-cbd-health-co-confirms-pet-products-progress-20181211-00283
According to the American Pet Products Association (APPA), $69.51 billion was spent on pets in the U.S in 2017 and it’s estimated that number will grow to $72.13 billion for 2018. Canadians spend $6.6 billion a year on their pets according to recent numbers.
Looking at how cannabis/CBD plays into the pet market, CTV reported, “In 2017, sales of cannabis products marketed for pets at medical and adult-use cannabis dispensaries was nearly $7 million in California, Colorado, Oregon and Washington, according to BDS Analytics. In Colorado, sales of pet products grew 49 per cent in 2017, versus growth across all product categories at 15 per cent, it said.”
Canopy Animal Health, stated as the global leader in cannabinoid science for pets, is a division of Canopy Health, a wholly owned subsidiary of Canopy Growth Corporation ( TSX:WEED ), ( NYSE:CGC ). In August they announced that approval had been received from the Veterinary Drug Directorate of Health Canada to research the effectiveness of cannabidiol (“CBD”) to treat anxiety in certain animals.
Continued: The research will be conducted by Canopy Animal Health, a division of Canopy Health which focuses on developing cannabis-based healthcare products for companion animals. The approval comes in the form of a No Objection Letter for the use of a proprietary CBD enriched oil formulation, previously administered in preclinical dosing and safety studies, as a potential therapy for anxiety. The CBD formulation will be produced by Canopy Growth in its GMP-certified production facility in Smiths Falls, Ontario.
apnews.com/5c65e315a5c1d368198990af1e744afe
Check out the company's website here for more information:
envirotechnologiesinternational.com/
Current research shows that there are several common CBD benefits for dogs, which are, 1) powerful painkiller (the ECS is involved in managing pain and CBD's pain killing properties are well documented}; 2) effective anticonvulsant (CBD helps control seizures, tremors, tics and spasms); 3) natural anti-inflammatory; 4) anxiety and stress reducer (anxiety in dogs often results in in barking, urination and defecation, chewing and aggression); 5) active antiemetic (reduces nausea and vomiting); and homeostasis promoter (proper functioning of the body).
"Pet owners are committed to their pet's health well-being and are willing to spend money on pet health products, which make this a multi-billion dollar market, worldwide," said Karren. "We hope to introduce our CBD pet products in 2019 as we believe that our CBD pet products will be superior to those currently offered in this huge industry and will create another profitable channel for our CBD products."
ETII was also mentioned in a NASDAQ article released today with a few other top name CBD brands:nasdaq.com/press-release/envirotechnologies-internationals-subsidiary-cbd-health-co-confirms-pet-products-progress-20181211-00283
According to the American Pet Products Association (APPA), $69.51 billion was spent on pets in the U.S in 2017 and it’s estimated that number will grow to $72.13 billion for 2018. Canadians spend $6.6 billion a year on their pets according to recent numbers.
Looking at how cannabis/CBD plays into the pet market, CTV reported, “In 2017, sales of cannabis products marketed for pets at medical and adult-use cannabis dispensaries was nearly $7 million in California, Colorado, Oregon and Washington, according to BDS Analytics. In Colorado, sales of pet products grew 49 per cent in 2017, versus growth across all product categories at 15 per cent, it said.”
Canopy Animal Health, stated as the global leader in cannabinoid science for pets, is a division of Canopy Health, a wholly owned subsidiary of Canopy Growth Corporation ( TSX:WEED ), ( NYSE:CGC ). In August they announced that approval had been received from the Veterinary Drug Directorate of Health Canada to research the effectiveness of cannabidiol (“CBD”) to treat anxiety in certain animals.
Continued: The research will be conducted by Canopy Animal Health, a division of Canopy Health which focuses on developing cannabis-based healthcare products for companion animals. The approval comes in the form of a No Objection Letter for the use of a proprietary CBD enriched oil formulation, previously administered in preclinical dosing and safety studies, as a potential therapy for anxiety. The CBD formulation will be produced by Canopy Growth in its GMP-certified production facility in Smiths Falls, Ontario.
apnews.com/5c65e315a5c1d368198990af1e744afe
Check out the company's website here for more information:
envirotechnologiesinternational.com/
関連の投稿
免責事項
これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。